American Society of Clinical Oncology

SHERPA: White

People

  1. Postow
    Postow
  2. Shoushtari
    Shoushtari
  3. Panageas
    Panageas
  4. Momtaz
    Momtaz
  5. D'Angelo
    D'Angelo
  6. Harding
    Harding
  7. Dickson
    Dickson
  8. Solit
    Solit
  9. Rosenberg
    Rosenberg
  10. Ariyan
    Ariyan

Groups

  1. Department of Medicine (327)
  2. Melanoma and Immunotherapeutics Service (327)
  3. Solid Tumor Oncology Division (327)
  4. GSK Faculty (189)
  5. Melanoma Disease Management Team (143)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  7. Hematologic Malignancies, Division of (102)
  8. Epidemiology and Biostatistics (81)
  9. Biostatistics Service (75)
  10. Survivorship Research (57)
Search Within
  1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Meeting Abstract (249)
  2. Journal Article (70)
  3. Editorial (6)
  4. Correspondence (1)
  5. Guidelines (1)
Groups
  1. Department of Medicine (327)
  2. Melanoma and Immunotherapeutics Service (327)
  3. Solid Tumor Oncology Division (327)
  4. GSK Faculty (189)
  5. Melanoma Disease Management Team (143)
  6. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)

More Groups

People
  1. Jedd Wolchok (171)
  2. Paul Chapman (94)
  3. Michael Postow (82)
  4. Alexander Shoushtari (63)
  5. Margaret Callahan (62)
  6. Katherine Panageas (42)

More People

Years
  1. 2023 (18)
  2. 2022 (20)
  3. 2021 (20)
  4. 2020 (17)
  5. 2019 (23)
  6. 2018 (33)

More Years

Publications
  1. Journal of Clinical Oncology (316)
  2. American Society of Clinical Oncology Educational Book (5)
  3. JCO Precision Oncology (5)
  4. JCO Clinical Cancer Informatics (1)

Results (327)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with BRAF V600-mutant melanoma
    Meeting Abstract

    Chapman, P. B.; Ascierto, P. A.; Schadendorf, D.; Grob, J. J.; Ribas, A.; Kiecker, F.; Dutriaux, C.; Demidov, L. V.; Lebbe, C.; Rutkowski, P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab (nivo) in advanced solid tumors; predicted vs observed pharmacokinetics (PK) in ICONIC
    Meeting Abstract

    Burris, H. A.; Callahan, M. K.; Tolcher, A. W.; Kummar, S.; Falchook, G. S.; Pachynski, R. K.; Tykodi, S. S.; Gibney, G. T.; Seiwert, T. Y.; Gainor, J. F.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy
    Meeting Abstract

    Ascierto, P. A.; Melero, I.; Bhatia, S.; Bono, P.; Sanborn, R. E.; Lipson, E. J.; Callahan, M. K.; Gajewski, T.; Gomez-Roca, C. A.; Hodi, F. S.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: A pooled analysis of randomized phase II and III trials
    Journal Article

    Schadendorf, D.; Wolchok, J. D.; Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C. D.; Chesney, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma
    Journal Article

    Sznol, M.; Ferrucci, P. F.; Hogg, D.; Atkins, M. B.; Wolter, P.; Guidoboni, M.; Lebbé, C.; Kirkwood, J. M.; Schachter, J.; Daniels, G. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma
    Journal Article

    Weber, J. S.; Hodi, F. S.; Wolchok, J. D.; Topalian, S. L.; Schadendorf, D.; Larkin, J.; Sznol, M.; Long, G. V.; Li, H.; Waxman, I. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy
    Journal Article

    Naidoo, J.; Wang, X.; Woo, K. M.; Iyriboz, T.; Halpenny, D.; Cunningham, J.; Chaft, J. E.; Segal, N. H.; Callahan, M. K.; Lesokhin, A. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: A pooled analysis
    Journal Article

    D'Angelo, S. P.; Larkin, J.; Sosman, J. A.; Lebbé, C.; Brady, B.; Neyns, B.; Schmidt, H.; Hassel, J. C.; Hodi, F. S.; Lorigan, P.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Reaffirming and clarifying the American Society of Clinical Oncology's policy statement on the critical role of phase I trials in cancer research and treatment
    Journal Article

    Weber, J. S.; Levit, L. A.; Adamson, P. C.; Bruinooge, S. S.; Burris, H. A. 3rd; Carducci, M. A.; Dicker, A. P.; Gönen, M.; Keefe, S. M.; Postow, M. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Updated results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067)
    Meeting Abstract

    Wolchok, J. D.; Chiarion-Sileni, V.; Gonzalez, R.; Rutkowski, P.; Grob, J. J.; Cowey, C. L.; Lao, C.; Schadendorf, D.; Ferrucci, P. F.; Smylie, M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save